Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
8.21
-0.01 (-0.12%)
At close: Apr 9, 2026, 4:00 PM EDT
8.10
-0.11 (-1.34%)
After-hours: Apr 9, 2026, 4:43 PM EDT
Rallybio Employees
Rallybio had 14 employees as of December 31, 2025. The number of employees decreased by 11 or -44.00% compared to the previous year.
Employees
14
Change
-11
Growth
-44.00%
Revenue / Employee
$61,286
Profits / Employee
-$641,286
Market Cap
43.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | -11 | -44.00% |
| Sep 30, 2025 | 15 | -10 | -40.00% |
| Jun 30, 2025 | 20 | -5 | -20.00% |
| Mar 31, 2025 | 24 | -6 | -20.00% |
| Dec 31, 2024 | 25 | -18 | -41.86% |
| Sep 30, 2024 | 25 | -19 | -43.18% |
| Jun 30, 2024 | 25 | -20 | -44.44% |
| Mar 31, 2024 | 30 | -13 | -30.23% |
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Sep 30, 2023 | 44 | 0 | - |
| Jun 30, 2023 | 45 | 0 | - |
| Mar 31, 2023 | 43 | 3 | 7.50% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Sep 30, 2022 | 44 | 13 | 41.94% |
| Jun 30, 2022 | 45 | 17 | 60.71% |
| Mar 31, 2022 | 40 | 12 | 42.86% |
| Dec 31, 2021 | 35 | 7 | 25.00% |
| Sep 30, 2021 | 31 | - | - |
| Jun 30, 2021 | 28 | - | - |
| Mar 31, 2021 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| NextCure | 40 |
| Lisata Therapeutics | 21 |
| Veru Inc. | 20 |
| Atossa Therapeutics | 15 |
| Sensei Biotherapeutics | 15 |
| Rein Therapeutics | 10 |
| RenovoRx | 10 |
RLYB News
- 5 weeks ago - Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
- 5 weeks ago - Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
- 7 weeks ago - Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
- 7 weeks ago - Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Business Wire
- 2 months ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
- 5 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 7 months ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
- 7 months ago - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program - Business Wire